Analysis examines link between bone turnover markers and fracture risk in osteoporosis trials

January 10, 2018, Wiley

Pooled data from 14 osteoporosis clinical trials of anti-resorptive drugs indicate that patients who have reduced levels of two bone turnover markers during treatment have lower risks of later experiencing vertebral fractures.

No were significantly associated with non-vertebral or hip fracture risks, according to the Journal of Bone and Mineral Research analysis.

The findings may be helpful in the development of anti-resorptive drugs for osteoporosis, particularly in choosing the dose and treatment schedule.

Explore further: Bone loss after denosumab, only partial protection with zoledronate

More information: Journal of Bone and Mineral Research (2018). DOI: 10.1002/jbmr.3355

Related Stories

Bone loss after denosumab, only partial protection with zoledronate

August 2, 2017
Denosumab is a monoclonal antibody which acts as a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis.

New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis

June 15, 2017
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 show that in postmenopausal women with osteoporosis, 12 months of treatment with romosozumab is associated with large, rapid ...

Task force provides guidance on use of osteoporosis drugs

January 19, 2016
A new report by a Task force of the American Society for Bone and Mineral Research provides guidance on the use of bisphosphonates, which are the most commonly used medications for osteoporosis.

Study provides insights on optimal treatment of Paget's disease of bone

February 8, 2017
In a study of patients with Paget's disease of bone—a common skeletal disorder that can lead to bone deformity, fractures, osteoarthritis, and bone pain—long-term intensive bisphosphonate therapy conferred no clinical ...

Once-yearly zoledronic acid benefits men with osteoporosis

November 2, 2012
(HealthDay)—For men with osteoporosis, a once-yearly infusion with zoledronic acid is associated with fewer vertebral fractures and improved bone health compared with placebo, according to a study published in the Nov. ...

Alendronate reduces adjacent-level vertebral fractures

December 30, 2013
(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue of Spine.

Recommended for you

Childhood abuse linked to greater risk of endometriosis, study finds

July 17, 2018
Endometriosis, a painful condition that affects one in 10 reproductive-age women in the U.S., has been linked to childhood physical and sexual abuse, according to findings published today in the journal Human Reproduction.

Why men might recover from flu faster than women

July 17, 2018
Men may recover more quickly from influenza infections because they produce more of a key lung-healing protein, a study from scientists at Johns Hopkins Bloomberg School of Public Health suggests.

Broadly acting antibodies found in plasma of Ebola survivors

July 17, 2018
Recent Ebola virus disease (EVD) outbreaks, including the 2013-2016 epidemic that ravaged West Africa and the 2018 outbreak in the Democratic Republic of the Congo, highlight the need for licensed treatments for this often-deadly ...

Hidden blood in feces may signal deadly conditions

July 17, 2018
(HealthDay)—Even if it's not visible to the naked eye, blood in the stool can be serious—a sign of a potentially fatal disease other than colon cancer, new research suggests.

Scientists a step closer to predicting epidemics

July 13, 2018
Ecologists at the University of Georgia have taken an important step in their efforts to develop an early warning system for infectious disease outbreaks.

Researchers identify target for novel malaria vaccine

July 13, 2018
A Yale-led team of researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.